Despite that the management of CRC patients has been based for decades on robust diagnostic methods such as colonoscopy, histopathological analysis of tumor tissue, molecular biology assays for molecular profiling, imaging methods (computer tomography or magnetic resonance), and serum tumor markers analysis (Carcinoembryonic antigen (CEA), Carbohydrate antigen 19-9 (CA 19-9), etc.), these strategies still have many limitations and do not fully satisfy clinical needs due to their lack of sensitivity and/or specificity to early disease detection even before clinical onset. Here, CEACAM5 is linked to colorectal carcinoma.